Heart failure & cardiomyopathiesCohort study

The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis

CirculationPublished

  • Retrospective cohort study
  • multiregistry (SHaRe and IPHCC)

Authors' conclusion

In pediatric HCM, massive LVH disproportionately affects those diagnosed in early childhood with sarcomeric disease, with increased risk for adverse events. Significant MLVWT regression is seen in nearly a quarter of patients.

Study context

Population
Patients with pediatric-onset hypertrophic cardiomyopathy (HCM) from 2 registries (SHaRe, IPHCC), encounters 1960/1970 through March 202454 female [30%]
Participants
587 patients
Exposure
Massive left ventricular hypertrophy (LVH) vs no massive LVH
  • Massive LVHn = 186

Main finding

As reported in the abstract

Composite outcomes, massive vs no massive LVH
Massive LVH vs No massive LVHEstimateP value
HCM-related mortality
unadjusted HR 3.3(95% CI 1.2–9.7)
P = 0.026
major adverse cardiac events
HR 2.6(CI 1.7–3.9)
P < 0.001
major ventricular arrhythmia
HR 3.1(CI 1.8–5.2)
P < 0.001
HF
HR 1.9(CI 1.1–3.1)
P = 0.013

Observational data: associations, not effects.

Further findings

Sarcomeric genetic variants

P = 0.034

OutcomeMassive LVHNo massive LVHP value
Age at diagnosismedian 9.2 (IQR 2.1–13.1) years13.6 (IQR 9.7–15.5) yearsP < 0.001

Serial maximal left ventricular wall thickness (MLVWT) in massive LVH (n=115 with serial data, 62%), first vs last measurement

Absolute MLVWT: median 26 mm [IQR 18-32 mm] vs 31 mm [26-35 mm]
P < 0.001
MLVWT z score: median +22 [IQR +18 to +26] vs +23 [+20 to +28]
P = 0.25
Last absolute MLVWT >5 mm less than largest recorded MLVWT
25 patients (22%)

Original publication

The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. Circulation. Published 17 April 2026. doi:10.1161/circulationaha.126.078843

Summarised from the published abstract; every number is checked against it